Uncategorized
Vision gains, retinopathy level sustained in RIDE/RISE extension study
WAILEA, Hawaii – Vision gains achieved at the conclusion of the RIDE/RISE studies were maintained in patients with diabetic macular edema who were enrolled in a 2-year open-label extension study, Michael S. Ip, MD, told colleagues at Retina 2015. Improvements in retinopathy level were also sustained.After 3 years in RIDE/RISE, 500 participants entered an open-label extension in which Lucentis 0.5 mg (ranibizumab, Genentech) was given as needed in all three treatment arms according to re-treatment criteria. Mean follow-up time was 14.1 months, less than the anticipated 24 months due to (Read more...)